Is CYTHW or JNJ a better dividend investment in 2026?

CYTHW currently yields 6250.00% with a 5% 5-year dividend growth rate. JNJ yields 2.13% with 5.8% growth. The better choice depends on your goal: CYTHW offers higher current income.

What is the dividend yield difference between CYTHW and JNJ?

CYTHW has a forward dividend yield of 6250.00% ($2.00/share annually). JNJ yields 2.13% ($5.20/share annually). The yield gap is 6247.87 percentage points.

Home › Compare › CYTHW vs JNJ

CYTHW vs JNJ: Dividend Comparison 2026

CYTHW yields 6250.00% · JNJ yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CYTHW wins by $547038161900822.19M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CYTHW

● Live price

6250.00%

Share price

$0.03

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$547038161900822.19M

Annual income

$530,345,833,482,145,900,000.00

Full CYTHW calculator →

JNJ

Johnson & Johnson

● Live price

2.13%

Share price

$244.44

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.3K

Annual income

$4,689.40

Full JNJ calculator →

Portfolio growth — CYTHW vs JNJ

📍 CYTHW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CYTHW	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CYTHW + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CYTHW pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYTHW

Annual income on $10K today (after 15% tax)

$531,250.00/yr

After 10yr DRIP, annual income (after tax)

$450,793,958,459,824,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$180.82/yr

After 10yr DRIP, annual income (after tax)

$3,985.99/yr

At 15% tax rate, CYTHW beats the other by $450,793,958,459,824,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYTHW + JNJ for your $10,000?

CYTHW: 50%JNJ: 50%

100% JNJ50/50100% CYTHW

Portfolio after 10yr

$273519080950411.09M

Annual income

$265,172,916,741,072,950,000.00/yr

Blended yield

96.95%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CYTHW

Analyst Ratings

Buy

Consensus: Buy

Altman Z

-46.3

Piotroski

2/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-6.4% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYTHW buys

JNJ buys

Politician	Chamber	Ticker	Type	Amount	Date
Thomas H. Kean	🏢 House	$JNJ	▼ Sell	$15,001 - $50,000	2026-01-23
Julie Johnson	🏢 House	$JNJ	▼ Sell	$1,001 - $15,000	2025-12-18
Lloyd Doggett	🏢 House	$JNJ	▲ Buy	$1,001 - $15,000	2025-12-09
Thomas H. Kean	🏢 House	$JNJ	▼ Sell	$15,001 - $50,000	2025-11-20
Julie Johnson	🏢 House	$JNJ	▼ Sell	$1,001 - $15,000	2025-11-13
Rich McCormick	🏢 House	$JNJ	▲ Buy	$1,001 - $15,000	2025-11-05
Ro Khanna	🏢 House	$JNJ	▲ Buy	$1,001 - $15,000	2025-10-30
Ro Khanna	🏢 House	$JNJ	▲ Buy	$1,001 - $15,000	2025-10-30
Ro Khanna	🏢 House	$JNJ	▲ Buy	$1,001 - $15,000	2025-10-30
Jared Moskowitz	🏢 House	$JNJ	▼ Sell	$1,001 - $15,000	2025-10-10

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCYTHWJNJ

Forward yield	6250.00% ✓	2.13%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$547038161900822.19M ✓	$30.3K
Annual income after 10y	$530,345,833,482,145,900,000.00 ✓	$4,689.40
Total dividends collected	$545916230838674.88M ✓	$15.4K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare
Analyst consensus	Buy	Buy

Year-by-year: CYTHW vs JNJ ($10,000, DRIP)

Year	CYTHW Portfolio	CYTHW Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$635,700	$625,000.00	$10,592	$272.30	+$625.1K → CYTHW
2	$37,812,208	$37,132,009.35	$11,289	$357.73	+$37.80M → CYTHW
3	$2,104,624,511	$2,064,165,448.17	$12,123	$472.89	+$2104.61M → CYTHW
4	$109,626,980,731	$107,375,032,504.06	$13,141	$629.86	+$109626.97M → CYTHW
5	$5,344,419,538,811	$5,227,118,669,428.94	$14,408	$846.81	+$5344419.52M → CYTHW
6	$243,874,608,189,950	$238,156,079,283,422.40	$16,021	$1,151.60	+$243874608.17M → CYTHW
7	$10,417,442,627,867,752	$10,156,496,797,104,504.00	$18,122	$1,588.22	+$10417442627.85M → CYTHW
8	$416,612,895,336,954,560	$405,466,231,725,136,060.00	$20,930	$2,228.20	+$416612895336.93M → CYTHW
9	$15,600,306,933,342,350,000	$15,154,531,135,331,807,000.00	$24,792	$3,191.91	+$15600306933342.32M → CYTHW
10	$547,038,161,900,822,200,000	$530,345,833,482,145,900,000.00	$30,274	$4,689.40	+$547038161900822.19M → CYTHW

CYTHW vs JNJ: Complete Analysis 2026

CYTHW — Stock

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.

Full CYTHW Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this CYTHW vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYTHW vs SCHD CYTHW vs JEPI CYTHW vs O CYTHW vs KO CYTHW vs MAIN CYTHW vs ABBV CYTHW vs MRK CYTHW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.